Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions.

Journal Article (Journal Article;Review)

Despite improvements in outcomes in the last few decades for heart failure (HF) with reduced ejection fraction (HFrEF), there still remains a need for novel therapies as many patients incompletely recover with existing therapies and progress to advanced HF. In this review, we will discuss recent advances in the management of HFrEF with a focus on upcoming therapies that hold the greatest promise for clinical use. We will discuss novel pharmacological therapies and areas of uncertainty with existing therapies. We will also discuss the potential utility and controversy surrounding novel interventions for HF such as percutaneous mitral valve repair, atrial fibrillation ablation, and other emerging interventions with positive signals for benefit in HFrEF. Finally, we will summarize the current state of stem cell and gene therapy for HFrEF and future directions.

Full Text

Duke Authors

Cited Authors

  • Reddy, YNV; Borlaug, BA; O'Connor, CM; Gersh, BJ

Published Date

  • May 7, 2020

Published In

Volume / Issue

  • 41 / 18

Start / End Page

  • 1764 - 1774

PubMed ID

  • 31199474

Electronic International Standard Serial Number (EISSN)

  • 1522-9645

Digital Object Identifier (DOI)

  • 10.1093/eurheartj/ehz364

Language

  • eng

Conference Location

  • England